Karuna Therapeutics, Inc., A Bristol Myers Squibb Company

This study looks at the long-term safety of a drug called KarXT for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). It is for people who have already completed a previous KarXT study. The goal is to see if KarXT is safe and tolerable over 52…

This study tests an experimental drug called KarXT to see if it can prevent the return of psychosis (hallucinations, delusions) in people with Alzheimer's disease. About 410 participants aged 55-90 will receive either KarXT or a placebo for 38 weeks. The main goal is to see if th…

This study checks the long-term safety of a drug called KarXT in teenagers (13-17) with schizophrenia, and KarXT plus KarX-EC in children (5-17) with irritability linked to autism. About 400 participants who completed earlier studies will take the drug openly for up to 2 years. T…

This study looks at the long-term safety of an investigational drug called KarXT when added to current antipsychotic treatment for people with schizophrenia whose symptoms are not well controlled. About 280 adults who completed a previous study will take KarXT for up to 52 weeks.…

This study tests an investigational drug called KarXT to see if it can safely reduce psychosis symptoms like hallucinations and delusions in people with Alzheimer's disease. The trial involves 406 adults aged 55 to 90 with mild to severe Alzheimer's and moderate to severe psychos…

This study tests an experimental drug called KarXT to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease. About 500 adults aged 55 to 90 with mild to severe Alzheimer's and moderate to severe psychosis will receive either KarXT or a placeb…

This study looks at how a new drug called KarXT changes the levels of three other drugs (midazolam, fexofenadine, and digoxin) in the body. It involves 60 healthy adults and aims to see if KarXT causes any drug interactions. The results will help doctors understand how to use Kar…

This study looks at how a person's genes (specifically CYP2D6) affect the way their body processes the drug KarXT. It involves 56 healthy adults who are grouped by their gene type. The goal is to understand drug levels and safety, not to treat any disease.

This study looks at how much of the drug KarXT gets into the breast milk and blood of healthy women who are breastfeeding. Eight mothers will take KarXT and provide milk and blood samples over 24 hours. The goal is to estimate how much of the drug a nursing baby might receive and…